Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Group 1 - Anebulo Pharmaceuticals, Inc. has initiated its Phase 1 single ascending dose study of intravenous selonabant in healthy young adults [1] - The study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA) [1] - This development focuses on providing novel solutions for individuals suffering from acute cannabinoid-induced toxicities [1]